To validate this point, future studies will have to investigate whether pharmacologic ACVR2B blockade, alone or in combination with routinely administered anti‐cancer drugs, is sufficient to enhance the anti‐proliferative effects of chemotherapy and/or to prevent its associated musculoskeletal defects. The gene discussed is ACVR2B; the disease is cancer.